iRegene Therapeutics
PrivateLast Round
Series C
Extension
Jul 2, 2026
Total Funding Raised
$170.7M
Company Overview
iRegene Therapeutics is a biotechnology company that develops chemically induced allogeneic cell therapies for the treatment of degenerative diseases such as Parkinson's disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
iRegene Therapeutics Comparables
Compare iRegene Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| XellSmart | 88% | |
| Kenai Therapeutics | 85% | |
| Hopstem Biotechnology | 82% |
iRegene Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jul 2, 2026 | ||||
| Series C | Jun 1, 2026 | ||||
| Series B | Sep 4, 2025 | ||||
| Series B Extension | Apr 11, 2025 | ||||
| Series B | Oct 13, 2024 | ||||
Series A Extension | Jan 24, 2022 |
iRegene Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ceyuan Ventures | Series B |
| Shanghai Guosheng Capital Management Co., Ltd. | Series B |
| China Capital Management Co., Ltd. | Series C Extension |
| Shenzhen New Industry Venture Capital | VC Round |
| Northern Light Venture Capital | Series B |
| Hony Capital | Series C Extension |
| Shenzhen Dachen Caizhi Venture Capital Management | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 23, 2026
Monthly visitors grew 386% MoM to 525.
- Sep 4, 2025
$42.1M round led by Northern Light Venture Capital.
iRegene Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about iRegene Therapeutics's valuation, stock price, and market status.
Is iRegene Therapeutics a public or private company?
iRegene Therapeutics is a private company.
What is the current stock price of iRegene Therapeutics?
iRegene Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is iRegene Therapeutics worth (valuation)?
Valuation information for iRegene Therapeutics is not publicly available.
Can I buy iRegene Therapeutics stock?
iRegene Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was iRegene Therapeutics's last funding round?
iRegene Therapeutics's most recent funding round was Series C on July 2, 2026.
Who are the main investors in iRegene Therapeutics?
Key investors in iRegene Therapeutics include Ceyuan Ventures, Northern Light Venture Capital, Shenzhen Dachen Caizhi Venture Capital Management.
Will iRegene Therapeutics IPO soon?
No public IPO plans have been announced for iRegene Therapeutics.
How can I track iRegene Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor iRegene Therapeutics's secondary market activity and sign up for updates.